{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-24-000061","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.047133+00:00","generated_at":"2026-06-02T00:48:40.018711+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated","bullets":["Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.","Cash, equivalents and marketable securities totaled $296.6M as of March 31, 2024; expected to fund operations into H1 2027.","First patient dosed in ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer's in May 2024.","Phase 1 subcutaneous dosing study of sabirnetug expected to start mid-2024; Lonza collaboration for manufacturing announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-24-000061","json":"https://secwatch.observer/filing/0001576885-24-000061.json","markdown":"https://secwatch.observer/filing/0001576885-24-000061.md","text":"https://secwatch.observer/filing/0001576885-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/0001576885-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/abos-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:48:40.018711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bc77e97adcb8c4b6d559943b8444b8f7676fca7","claim":"Acumen Pharmaceuticals, Inc. reported first quarter of 2024 results: net income $14.9 million.","evidence_excerpt":"Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/0001576885-24-000061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"$14.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}